An Open Label Long-term Extension study to investigate the safety of PF-06823859 Administered to Adult Participants with Active Dermatomyositis (C0251008)
Brief description of study
The purpose of this study (C0251008) is to evaluate the long-term safety, and effectiveness of PF06823859 (active study drug) in adult participants with dermatomyositis (DM) from a qualifying study (such as the C0251002 study). The C0251008 study was established to allow participants who were participating in a qualifying study to continue on active treatment for an additional 48 weeks. All participants entering the C0251008 study will receive active study drug treatment, 600 mg IV every 4 weeks. At week 52, participants will enter into a follow up period of 16 weeks. Overall, the C0251008 study will be 68 weeks duration, with visits occurring every 4 weeks.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
